New report shows nearly 300 cell and gene therapies in development
By Andrew Powaleny | December 6, 2018
Fifty years ago, the idea of altering a gene to treat or even cure a disease was considered science fiction. Today, cell and gene therapy are transforming treatment options for some patients and...
Read More
World AIDS Day 2018: Hope for the future
By Andrew Powaleny | December 1, 2018
Each year, I write to commemorate World AIDS Day which is now in its 30th year spotlighting patients living with HIV and those we’ve sadly lost to AIDS-related illnesses.
Read More
Groups sound the alarm on administration’s new Part B proposal
By Nicole Longo | November 14, 2018
Last month, the Administration announced a dangerous new proposal, the International Pricing Index Model, that would upend the delivery of Medicare Part B medicines. As PhRMA President and CEO...
Read More
4 things you need to know about the administration’s latest Part B proposal
By Nicole Longo | November 5, 2018
The Department of Health and Human Services (HHS) recently released an Advance Notice of Proposed Rulemaking regarding Medicare Part B that puts patient access to medicines and Part B at risk....
Read More
PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation
By Douglas Petersen | November 2, 2018
International trade is critical to delivering life-saving and life-enhancing medicines in the global economy, which is why PhRMA addresses several discriminatory foreign government practices in...
Read More
PhRMA CEO discusses industry’s new approach to DTC television advertising
By Holly Campbell | October 17, 2018
PhRMA president and CEO Stephen J. Ubl joined CBS This Morning and MSNBC Live with Ali Velshi to discuss PhRMA member companies’ commitment to providing patients with the information they need to...
Read More
FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies
By Richard Moscicki, M.D. | October 16, 2018
The U.S Food and Drug Administration (FDA) plays a critical role in protecting and promoting the health of all Americans. Every day, the FDA does important work to ensure the safety, efficacy and...
Read More
What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising
By Holly Campbell | October 15, 2018
Pharmaceutical Research and Manufacturers of America (PhRMA) member companies today announced their commitment to providing more transparency about medicine costs to help patients make more...
Read More
Americans want to know more than just the list price of a medicine—and we’re answering their call
By Robert Zirkelbach | October 15, 2018
The biopharmaceutical industry is answering the call to provide more information about medicine costs. As innovators of life-saving therapies, we recognize the importance of giving people the...
Read More
Balancing innovation and competition in the biologics marketplace
By David Korn | October 11, 2018
Last month, I presented at the U.S. Food and Drug Administration’s (FDA) Public Hearing on Facilitating Competition and Innovation in the Biological Products Marketplace. The hearing was part of...
Read More
Medicare Monday (100)
340B Spotlight (37)
Cost & Consequence (0)
